Prosensa strengthens management team
Leiden, February 27, 2009 – Prosensa, the Dutch based biopharmaceutical company focusing on RNA modulating therapeutics today announced that it has strengthened its management team with several new key appointments.
Hans GCP Schikan has been appointed as the new Chief Executive Officer. Mr. Schikan will be responsible for all of Prosensa’s corporate functions and the overall management and strategic direction of the company. He brings to Prosensa more than 20 years of corporate experience in the pharma and biotech industry.
Mr. Schikan was previously at Genzyme where he was responsible for the global marketing and strategy development of the genetic disease portfolio of orphan medicinal products, which includes the first treatment for Pompe disease. Mr. Schikan commented, “I look forward to working with the highly professional and talented team at Prosensa. It is a privilege to contribute to the mission of building a fully integrated biopharmaceutical company which provides hope to patients and their families.”
“Hans has tremendous experience that will be very valuable to Prosensa. The executive-level roles he has held include managing director positions and commercial roles in business development and strategic marketing. In addition Hans has a deep understanding of the orphan medicinal products space in general and the launch of novel treatments in the neuromuscular field in particular. With his strong history as a results-driven leader, I am confident that he will take Prosensa to the next level as a leading company in the field of RNA modulation with one of the most advanced product pipelines in Duchenne Muscular Dystrophy, based on its proprietary exon skipping platform”, said Daan Ellens, Chairman of the Board.
Gerard Platenburg, who until recently served as Prosensa’s CEO, has been appointed Chief Development Officer. Mr. Ellens said, “Gerard, as one of the founders of Prosensa, has taken the company from an initial idea to an established player in RNA modulation. His contribution has been enormous and in this new phase of the company, he will focus on the successful development of Prosensa’s pipeline towards regulatory approval.”
Apart from Mr. Schikan, other new members of Prosensa’s reinforced management team include Luc Dochez, VP for Business Development, Roelck Cuperus, VP for Regulatory Affairs and Richard Holslag, VP for Manufacturing.
Mr. Dochez has over 10 years experience in the biotech industry. Most recently he was VP Business Development at TiGenix NV and President of TiGenix Inc. Mrs. Cuperus worked at amongst others Genzyme and Genencor and has over 15 years of regulatory experience. Mr. Holslag has more than 30 years experience in manufacturing operations. Most recently he worked with Crucell, successfully leading several international projects.